Trial Profile
Study evaluating the effect of belatacept after switching from calcineurin inhibitors (CNIs) or mTOR inhibitors in kidney transplant recipients with severely impaired renal function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2016
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2016 New trial record